The National Institutes of Health (NIH) recently awarded two large grants to University of Alabama researchers. A $2.5 million--four year--grant will support research into heart failure. A second, $2.3--four year--grant with be used to research treatment-resistant high blood pressure.Read More
Science Market Update
Tags: Bioresearch funding, Alabama, University of Alabama, University of Alabama Birmingham, UAlab, UAB, NIH funding, University of Alabama at Birmingham, BioResearch Product Faire, Bioresearch Grant, Cardiac Disease
According to an article for UAB News, 40% of individuals infected with HIV are not currently receiving antiretroviral therapy, which means their disease is not suppressed. The University of Alabama, Birmingham’s Center for AIDS Research recently partnered with state and local agencies in signing the Paris Declaration to eliminate the spread of HIV/AIDS by 2030. Birmingham is the 13th U.S. city to commit to achieving the Declaration’s goals.Read More
Tags: Bioresearch funding, AIDS Research, Alabama, University of Alabama, University of Alabama Birmingham, UAlab, UAB, NIH funding, University of Alabama at Birmingham, BioResearch Product Faire, Bioresearch Grant, NIH awards 2017
Last year, the University of Alabama at Birmingham Comprehensive Cancer Center was awarded a five-year, $29 million grant for the National Cancer Institute. The Cancer Center now receives nearly $6M a year in NCI core funding and will continue to do so through 2021. In addition to this core grant, UAB CCC has received over $8.5M in research funding from the NCI during the first half of 2017. This brings their total NCI funding to $14.5 million.Read More
Tags: Bioresearch funding, cancer research, Alabama, University of Alabama, Cancer Treatment, Cancer, University of Alabama Birmingham, UAlab, UAB, University of Alabama at Birmingham, Cancer Center, cancer researchers, fight cancer, cancer reserach, Bioresearch Grant, Comprehensive Cancer Center
Parkinson’s is a degenerative condition that affects over one million Americans - even greater than the number of those suffering from multiple sclerosis, muscular dystrophy and Lou Gehrig's disease combined. There is no cure, but this month researchers at the University of Alabama at Birmingham made two important breakthroughs for treating the disease. One group of researchers has discovered the cause of the negative side-effects of L-DOPA and a potential way to counter-act it. Another group of researchers have “discovered an interaction in neurons that contributes to Parkinson’s Disease and they have shown that drugs now under development may block the process.”
(Image of the University of Alabama, Birmingham courtesy of Jaymay via Wikimedia Commons)Read More
(Image courtesy of Wikimedia commons)
University of Alabama at Birmingham received a $29 million grant from the National Cancer Institute. This five year core grant will support six research programs at the UAB Comprehensive Cancer Center. The renewal of the Cancer Center Support Grant, the most prestigious federal grant that a cancer research and treatment program can earn, also extends UAB’s elite “comprehensive” designation. According to the UAB News website this designation is awarded for scientific excellence and the ability to integrate diverse research approaches in the fight against cancer.Read More
Tags: Bioresearch funding, cancer research, Alabama, University of Alabama, Cancer Treatment, Cancer, University of Alabama Birmingham, UAlab, UAB, University of Alabama at Birmingham, Cancer Center, cancer researchers, fight cancer, 2016, cancer reserach, Bioresearch Grant, Comprehensive Cancer Center
Researchers at the University of Alabama, Birmingham have discovered a potential new approach to reducing the damage done by Parkinson's disease. They found that suppressing a key cell-signaling pathway in the brain lessened the destructive inflammation and nerve degradation in the area of the brain affected by Parkinson’s. In the study, rats were used to model the disease by inducing an overexpression of a-synuclein, a protein that is abundant in the human brain. The accumulation of α-synuclein is a core feature of Parkinson’s disease. This accumulation leads to the activation of the brain's immune cells and the production of inflammatory signaling chemicals, which leads to neurodegradation. The rats that were then given a JAK/STAT pathway inhibitors (known as Jakinibs) did not have the immune response, the inflammatory activation, or the neurodegeneration that those that did not receive the inhibitor experienced.Read More
(Photo courtesy of of wikimedia commons)
With Zika outbreaks in Mexico, Central America, and South America, the National Institute of Child Health and Human Development (NICHD) is attempting to stop the virus at our border. To assist with this effort, the institute is funding a study led by Dr. William Britt, Professor of Pediatric Infectious Diseases at the University of Alabama at Birmingham (UAB). This study will take place in Brazil, where the World Health Organization (WHO) estimates that between 500,000 and 1.5 million people have been infected by Zika. The study will follow pregnant women in Brazil regardless of their Zika virus infection status and follow the infants suspected of having Zika from birth until 2 years of age.Read More
Researchers at the University of Alabama recently received $8.1 million in life science funding from the National Institutes of Health for a study involving the etiology of geographic and racial differences in stroke. The life science grant was awarded in January of 2014 by the National Institute of Neurological Disorders and Stroke, a branch within the National Institutes of Health.
The University of Alabama is an unexpected standout in the science research marketplace. This campus ranks among the top in the nation, flanking closely with the top NIH funded universities, and yet there is surprisingly little sales rep traffic on campus.
The University of Alabama at Birmingham has been awarded a $7 million research grant to continue its leadership in pioneering clinical trials in the treatment of neurofibromatosis 1 and 2 and schwannomatosis, all rare genetic diseases. According to the Birmingham Business Journal, the circumstances of these diseases lead to non-cancerous tumors forming on the nerves and potentially causing blindness, hearing loss, learning disabilities, pain or deformity.